** Shares of Mesoblast rise as much as 46% to A$2.890, their highest since Dec. 16, 2020
** Stock posts its biggest intraday percentage rise since April 2
** Drug developer says U.S. Food and Drug Administration approved co's cell therapy for graft-versus-host disease
** About 28.1 mln shares change hands, compared with the 30-day average volume of around 6.3 mln
** Stock up over 825% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.